Interim Clinical Commissioning Policy: Thrombopoietin receptor agonists as first line therapy for new or relapsed immune thrombocytopenia in adults and children over the age of 1 year during the COVID-19 pandemic

Document first published:
Page updated:
Topic:
,
Publication type:

The policy is for thrombopoietin receptor agonists as first line therapy for new or relapsed acute immune thrombocytopenia in adults and children over the age of 1 year.